Korean biopharma looks for the perfect IPO formula

Expect a slew of biopharmaceutical IPOs from Korea, as companies capitalise on Seoul’s ambition to develop a biotechnology hub. That's if politics doesn't get in the way.

A clutch of South Korean biopharmaceutical companies plan to go public this year, raising capital to expand production capacity as the country strives to become a global powerhouse for the manufacture of biopharmaceutical products.

The batch of newcomers could reshape the pharmaceuticals sector they are bigger than most existing listed players and will potentially add liquidity and attract more foreign investment to one of the hottest sectors in the Korean market.

The moves reflect a strong demand for quality healthcare assets and favourable IPO rules. Yet the political scandal gripping the country could yet impact this promising growth story.

First out of the blocks...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222